Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.
Alzheimer's disease (AD) is the most common progressive dementia and is pathologically characterized by brain deposition of amyloid-beta (Abeta) peptide as senile plaques. Inflammatory and immune response pathways are chronically activated in AD patient brains at low levels, and likely play a role in disease progression. Like microglia, activated astrocytes produce numerous acute-phase reactants and proinflammatory molecules in the AD brain. One such molecule, S100B, is highly expressed by reactive astrocytes in close vicinity of beta-amyloid deposits. We have previously shown that augmented and prolonged activation of astrocytes has a detrimental impact on neuronal survival. Furthermore, we have implicated astrocyte-derived S100B as a candidate molecule responsible for this deleterious effect. To evaluate a putative relationship between S100B and AD pathogenesis, we crossed transgenic mice overexpressing human S100B (TghuS100B mice) with the Tg2576 mouse model of AD, and examined AD-like pathology. Brain parenchymal and cerebral vascular beta-amyloid deposits and Abeta levels were increased in bigenic Tg2576-huS100B mice. These effects were associated with increased cleavage of the beta-C-terminal fragment of amyloid precursor protein (APP), elevation of the N-terminal APP cleavage product (soluble APPbeta), and activation of beta-site APP cleaving enzyme 1. In addition, double transgenic mice showed augmented reactive astrocytosis and microgliosis, high levels of S100 expression, and increased levels of proinflammatory cytokines as early as 7-9 months of age. These results provide evidence that (over)-expression of S100B acts to accelerate AD-like pathology, and suggest that inhibiting astrocytic activation by blocking S100B biosynthesis may be a promising therapeutic strategy to delay AD progression..
Mori
Takashi
T
Department of Medical Science, Saitama Medical Center and University, Kawagoe, Saitama, Japan. t_mori@saitama-med.ac.jp
Koyama
Naoki
N
Arendash
Gary W
GW
Horikoshi-Sakuraba
Yuko
Y
Tan
Jun
J
Town
Terrence
T
D000544:Alzheimer Disease / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D016564:Amyloid beta-Protein Precursor / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D001253:Astrocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016657:Cerebral Amyloid Angiopathy / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D002540:Cerebral Cortex / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005786:Gene Expression Regulation / Q000235:genetics*; D005911:Gliosis / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017628:Microglia / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009414:Nerve Growth Factors / Q000235:genetics / Q000378:metabolism*; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D058225:Plaque, Amyloid / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D017434:Protein Structure, Tertiary / Q000502:physiology; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000235:genetics / Q000378:metabolism*
D016564:Amyloid beta-Protein Precursor; D016207:Cytokines; D009414:Nerve Growth Factors; D010446:Peptide Fragments; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human; C579159:S100b protein, mouse
Subcell Biochem. 2007;42:229-48
17612054
J Pharmacol Exp Ther. 2006 Aug;318(2):571-8
16709678
J Neurochem. 2000 Jan;74(1):295-301
10617132
Neurobiol Aging. 1999 Nov-Dec;20(6):581-9
10674423
J Neuroinflammation. 2005 Oct 31;2:24
16259628
Neurology. 1996 Jun;46(6):1592-6
8649554
J Neurochem. 1997 Dec;69(6):2294-301
9375660
J Neurosci. 2001 Jan 15;21(2):372-81
11160418
Stroke. 2008 Jul;39(7):2114-21
18451356
Biochim Biophys Acta. 1999 Jul 8;1450(3):191-231
10395934
Neurobiol Aging. 2000 May-Jun;21(3):383-421
10858586
Neurology. 1998 Apr;50(4):986-90
9566383
Nature. 1999 Jul 8;400(6740):173-7
10408445
Neuroepidemiology. 2004 Jul-Aug;23(4):159-69
15279021
Glia. 2005 Jun;50(4):281-6
15846807
Biochem Biophys Res Commun. 2004 Jul 2;319(3):733-7
15184044
Nat Med. 2000 Aug;6(8):916-9
10932230
J Neuropathol Exp Neurol. 1996 Mar;55(3):273-9
8786385
Neurobiol Aging. 2001 Nov-Dec;22(6):983-91
11755007
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1550-5
9037091
J Neurosci. 1992 Nov;12(11):4337-46
1432098
J Cereb Blood Flow Metab. 2002 Jun;22(6):723-34
12045671
J Neurosci. 2006 Jan 11;26(2):365-71
16407531
J Cereb Blood Flow Metab. 2004 Jun;24(6):646-56
15181372
Nat Med. 2008 Jun;14(6):681-7
18516051
Nature. 2006 Mar 16;440(7082):352-7
16541076
Nat Neurosci. 2002 Dec;5(12):1288-93
12402041
Neurobiol Aging. 2001 Sep-Oct;22(5):765-72
11705636
J Cereb Blood Flow Metab. 2005 Jun;25(6):748-62
15689951
Brain Pathol. 1998 Jan;8(1):65-72
9458167
J Cereb Blood Flow Metab. 2002 Jun;22(6):711-22
12045670
Neurobiol Aging. 2001 Nov-Dec;22(6):915-22
11754999
J Neurosci. 2000 Aug 1;20(15):5709-14
10908610
Ann Neurol. 2004 Jul;56(1):61-7
15236402
Science. 1996 Oct 4;274(5284):99-102
8810256
Nat Rev Neurosci. 2001 Mar;2(3):185-93
11256079
Trends Neurosci. 1997 Dec;20(12):570-7
9416670
J Neurosci. 2005 Nov 30;25(48):11125-32
16319312
Am J Pathol. 1999 Jun;154(6):1673-84
10362792
Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):127-42
15857298
Stroke. 2001 May;32(5):1208-15
11340235
CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27
19355932
Am J Pathol. 2007 Feb;170(2):680-92
17255335
J Neurosci. 2001 Nov 1;21(21):8370-7
11606625
Nature. 2002 Jan 31;415(6871):536-41
11823861
Glia. 2003 Jan 15;41(2):169-79
12509807
Neurobiol Aging. 1998 Sep-Oct;19(5):401-5
9880042